Comparison of governance approaches for the control of antimicrobial resistance: Analysis of three European countries.

Publisher: BioMed Central Country of Publication: England NLM ID: 101585411 Publication Model: eCollection Cited Medium: Internet ISSN: 2047-2994 (Electronic) Linking ISSN: 20472994 NLM ISO Abbreviation: Antimicrob Resist Infect Control Subsets: MEDLINE

Original Publication: London : BioMed Central

Drug Resistance, Bacterial* ; Government* ; Health Policy*; Delivery of Health Care/*organization & administration; Anti-Bacterial Agents/pharmacology ; England ; Europe ; France ; Germany ; Government Regulation ; Health Personnel ; Humans ; Infection Control/organization & administration

Policy makers and governments are calling for coordination to address the crisis emerging from the ineffectiveness of current antibiotics and stagnated pipe-line of new ones - antimicrobial resistance (AMR). Wider contextual drivers and mechanisms are contributing to shifts in governance strategies in health care, but are national health system approaches aligned with strategies required to tackle antimicrobial resistance? This article provides an analysis of governance approaches within healthcare systems including: priority setting, performance monitoring and accountability for AMR prevention in three European countries: England, France and Germany. Advantages and unresolved issues from these different experiences are reported, concluding that mechanisms are needed to support partnerships between healthcare professionals and patients with democratized decision-making and accountability via collaboration. But along with this multi-stakeholder approach to governance, a balance between regulation and persuasion is needed.
Competing Interests: Not applicableNot applicableThe authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

J Hosp Infect. 2008 Oct;70 Suppl 1:11-6. (PMID: 18994676)
PLoS One. 2012;7(8):e42787. (PMID: 22880109)
Health Econ Policy Law. 2010 Jan;5(Pt 1):31-52. (PMID: 19732476)
Lancet. 2016 Jan 16;387(10015):285-95. (PMID: 26603921)
Nat Med. 2008 Feb;14(2):107. (PMID: 18256603)
Int J Med Microbiol. 2015 Oct;305(7):799-806. (PMID: 26358916)
Milbank Q. 2014 Dec;92(4):754-75. (PMID: 25492603)
One Health. 2016 Oct 28;2:161-163. (PMID: 28616493)
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jul;56(7):903-12. (PMID: 23807401)
Lancet. 2016 May 28;387(10034):2177-9. (PMID: 27145702)
Milbank Q. 2011 Jun;89(2):167-205. (PMID: 21676020)
J Hosp Infect. 2011 Feb;77(2):123-8. (PMID: 20884081)
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Nov;55(11-12):1474-82. (PMID: 23114447)
Soc Sci Med. 2006 Oct;63(8):2141-52. (PMID: 16782254)
Lancet. 2016 Jan 16;387(10015):296-307. (PMID: 26603920)
Health Policy. 2012 Jun;106(1):37-49. (PMID: 22265340)
J Antimicrob Chemother. 2013 Apr;68(4):954-9. (PMID: 23194721)
Am J Disaster Med. 2012 Summer;7(3):175-88. (PMID: 23140061)
J Hosp Infect. 2015 Dec;91(4):338-45. (PMID: 26542950)
J Patient Saf. 2017 Dec;13(4):243-248. (PMID: 25706909)
J Med Syst. 2012 Oct;36(5):3135-9. (PMID: 22052129)
Euro Surveill. 2010 Feb 18;15(7):. (PMID: 20184852)
AMIA Annu Symp Proc. 2006;:244-8. (PMID: 17238340)
Infection. 2016 Jun;44(3):395-439. (PMID: 27066980)
Qual Saf Health Care. 2010 Dec;19(6):e45. (PMID: 20584705)
BMJ. 2005 Nov 19;331(7526):1199-201. (PMID: 16293845)
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jul;56(7):996-1002. (PMID: 23807408)
Health Econ Policy Law. 2016 Jan;11(1):17-38. (PMID: 25819303)
Bull World Health Organ. 2015 Dec 1;93(12):867-76. (PMID: 26668439)
J Hosp Infect. 2016 Sep;94(1):41-7. (PMID: 26996088)

United Kingdom Wellcome Trust

Keywords: Antimicrobial resistance; Europe; Governance; Healthcare settings; Infection control

0 (Anti-Bacterial Agents)

Date Created: 20180223 Date Completed: 20190719 Latest Revision: 20231112

20240628

PMC5819189

10.1186/s13756-018-0321-5

29468055